NCT07299721

Brief Summary

Congenital heart defects affect 1 in 100 births in France, with rising prevalence due to better care. Despite improved survival, 40% of children post-surgery face neurological impairments, and some of them show brain lesions. Causes include heart defects, genetic syndromes, and surgeries. Some heart defects and support systems increase cerebral risks. Monitoring cerebral perfusion is difficult to assess but emerging ultrafast ultrasound offers real-time, non-invasive blood flow insights.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
33mo left

Started Jan 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress12%
Jan 2026Jan 2029

First Submitted

Initial submission to the registry

November 19, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 23, 2025

Completed
9 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2029

Expected
Last Updated

December 23, 2025

Status Verified

December 1, 2025

Enrollment Period

Same day

First QC Date

November 19, 2025

Last Update Submit

December 9, 2025

Conditions

Keywords

Congenital Heart DiseasePaediatricCardiac ImagingUltrafast ultrasounf

Outcome Measures

Primary Outcomes (2)

  • Cerebral blood volume variation

    Depending on stage of medico-surgical treatment

    at baseline

  • Cerebral blood volume variation

    Depending on hemodynamic or ventilatory situation, and exposure to vasoactive or neuroactive drugs.

    at baseline

Secondary Outcomes (13)

  • Evolution of Arterial blood pressure

    at baseline

  • Evolution of central venous blood pressure

    at baseline

  • Evolution of left atrial pressure

    at baseline

  • Evolution of SpO2

    at baseline

  • Evolution of SaO2

    at baseline

  • +8 more secondary outcomes

Study Arms (1)

Patient receiving a transcranial Doppler

Every patient receiving a transcranial Doppler in routine care in our CHD unit of intensive care and anaesthesiology for cardiovascular surgery department

Other: Ultrafast ultrasound (UFUS)

Interventions

Ultrafast ultrasound imaging(UFUS), ultrasound images at a very high rate, using a Verasonics system (ultrasound open platform).

Patient receiving a transcranial Doppler

Eligibility Criteria

Age0 Years - 2 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Every patient, under two years old, receiving a transcranial Doppler in routine care in our CHD unit of intensive care and anaesthesiology for cardiovascular surgery department.

You may qualify if:

  • Every patient under 2 years old any sex or gender hospitalised in the congenital heart disease unit of the intensive care and anaesthesia for cardiovascular surgery, CHU de Bordeaux.
  • Open anterior fontanella
  • congenital heart disease
  • cardiac shock necessitating mechanical circulatory support.
  • Social security affiliation
  • Parental or legal guardian's non-opposition

You may not qualify if:

  • Anechoic
  • Allergy to echocardiography gel.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Haut Lévêque Cardiology Hospital

Pessac, France, 33604, France

Location

Related Links

MeSH Terms

Conditions

Heart Defects, Congenital

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 19, 2025

First Posted

December 23, 2025

Study Start

January 1, 2026

Primary Completion

January 1, 2026

Study Completion (Estimated)

January 1, 2029

Last Updated

December 23, 2025

Record last verified: 2025-12

Locations